309 The role of tumor-draining lymph nodes in the tuning of systemic T cell immunity by CTLA-4 blockade is revealed by local delivery of tremelimumab in early-stage melanoma: data from a Phase-I trial
BackgroundThe sentinel lymph node (SLN) is the first node to receive lymphatic drainage from the primary tumor and the site where naïve T cells are first primed. As such it is of great importance in initiating an effective anti-tumor immune response and an attractive target for immunomodulatory agen...
Saved in:
| Published in: | Journal for immunotherapy of cancer Vol. 8; no. Suppl 3; p. A336 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BMJ Publishing Group LTD
01.11.2020
BMJ Publishing Group |
| Subjects: | |
| ISSN: | 2051-1426 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | BackgroundThe sentinel lymph node (SLN) is the first node to receive lymphatic drainage from the primary tumor and the site where naïve T cells are first primed. As such it is of great importance in initiating an effective anti-tumor immune response and an attractive target for immunomodulatory agents. Pre-clinical studies have reported that i.t. administration of anti-CTLA-4 is as effective in inducing tumor eradication as systemic delivery, without the risk of treatment related side effects. However, it remains unclear whether this is due primarily to modulation of the tumor microenvironment or of tumor-draining lymph nodes (TDLN). Here, we have evaluated the safety, tolerability and immunomodulatory effects in the SLN and peripheral blood mononuclear cells (PBMC) of anti-CTLA-4/tremelimumab, delivered locally at the tumor excision site in patients with early-stage melanoma. This unique setting (post tumor excision but prior to SLN biopsy) allowed us to clinically assess the role of TDLN in the biological efficacy of CTLA-4 blockade.MethodsIn this phase I dose-escalation trial, patients with clinical stage I-II melanoma received one intradermal injection of tremelimumab at four dose levels (2, 5, 10 [n=3 each] or 20 mg [n=4]) around the primary excision site of the tumor, seven days prior to re-excision and SLN biopsy. Flow cytometry was performed to study viable cells from melanoma SLN and PBMC (prior to tremelimumab administration [day 0], and at 7 days, 3 weeks and 3 months after tremelimumab injection). Systemic melanoma antigen (MART-1/NY-ESO-1)-specific T cells responses were assessed by IFN-γ ELISPOT assay.ResultsIntradermal delivery of tremelimumab was safe and well tolerated. In terms of biological efficacy it selectively induced profound and durable decreases in Treg frequencies in both SLN and PBMC, decreased systemic MDSC rates, activated migratory dendritic cell subsets in the SLN, and induced T cell activation (by HLA-DR and ICOS up-regulation), both in SLN and PBMC. Moreover, systemic anti-melanoma T cell responses were induced (n=5) or boosted (n=2), in association with T cell activation and central-memory T cell differentiation. Of note, tumor recurrences so far were only observed in two patients who did not develop a systemic anti-tumor T cell response.ConclusionsThese findings indicate that i.d. administration of anti-CTLA-4 may offer a safe and promising adjuvant treatment strategy for patients with early-stage melanoma. Moreover, they demonstrate a central role for TDLN in the biological efficacy of CTLA-4 blockade and warrant the development of TDLN-targeted delivery methods for anti-CTLA-4.AcknowledgementsThis study received funding from the Harry J. Lloyd Charitable Trust; tremelimumab was provided by Pfizer Inc.Trial RegistrationNCT04274816Ethics ApprovalThe study was approved by the Medical Ethics Committee of the VU University Medical Center and Spaarne Gasthuis. |
|---|---|
| AbstractList | BackgroundThe sentinel lymph node (SLN) is the first node to receive lymphatic drainage from the primary tumor and the site where naïve T cells are first primed. As such it is of great importance in initiating an effective anti-tumor immune response and an attractive target for immunomodulatory agents. Pre-clinical studies have reported that i.t. administration of anti-CTLA-4 is as effective in inducing tumor eradication as systemic delivery, without the risk of treatment related side effects. However, it remains unclear whether this is due primarily to modulation of the tumor microenvironment or of tumor-draining lymph nodes (TDLN). Here, we have evaluated the safety, tolerability and immunomodulatory effects in the SLN and peripheral blood mononuclear cells (PBMC) of anti-CTLA-4/tremelimumab, delivered locally at the tumor excision site in patients with early-stage melanoma. This unique setting (post tumor excision but prior to SLN biopsy) allowed us to clinically assess the role of TDLN in the biological efficacy of CTLA-4 blockade.MethodsIn this phase I dose-escalation trial, patients with clinical stage I-II melanoma received one intradermal injection of tremelimumab at four dose levels (2, 5, 10 [n=3 each] or 20 mg [n=4]) around the primary excision site of the tumor, seven days prior to re-excision and SLN biopsy. Flow cytometry was performed to study viable cells from melanoma SLN and PBMC (prior to tremelimumab administration [day 0], and at 7 days, 3 weeks and 3 months after tremelimumab injection). Systemic melanoma antigen (MART-1/NY-ESO-1)-specific T cells responses were assessed by IFN-γ ELISPOT assay.ResultsIntradermal delivery of tremelimumab was safe and well tolerated. In terms of biological efficacy it selectively induced profound and durable decreases in Treg frequencies in both SLN and PBMC, decreased systemic MDSC rates, activated migratory dendritic cell subsets in the SLN, and induced T cell activation (by HLA-DR and ICOS up-regulation), both in SLN and PBMC. Moreover, systemic anti-melanoma T cell responses were induced (n=5) or boosted (n=2), in association with T cell activation and central-memory T cell differentiation. Of note, tumor recurrences so far were only observed in two patients who did not develop a systemic anti-tumor T cell response.ConclusionsThese findings indicate that i.d. administration of anti-CTLA-4 may offer a safe and promising adjuvant treatment strategy for patients with early-stage melanoma. Moreover, they demonstrate a central role for TDLN in the biological efficacy of CTLA-4 blockade and warrant the development of TDLN-targeted delivery methods for anti-CTLA-4.AcknowledgementsThis study received funding from the Harry J. Lloyd Charitable Trust; tremelimumab was provided by Pfizer Inc.Trial RegistrationNCT04274816Ethics ApprovalThe study was approved by the Medical Ethics Committee of the VU University Medical Center and Spaarne Gasthuis. |
| Author | Eertwegh, Alfons van den Chondronasiou, Dafni Stam, Anita Vuylsteke, Ronald Pul, Kim van Notohardjo, Jessica Gruijl, Tanja de Lougheed, Sinead Tol, Petrousjka van den Jooss, Karin |
| Author_xml | – sequence: 1 givenname: Jessica surname: Notohardjo fullname: Notohardjo, Jessica organization: Spaarne Gasthuis, Haarlem, Netherlands – sequence: 2 givenname: Kim van surname: Pul fullname: Pul, Kim van organization: Spaarne Gasthuis, Haarlem, Netherlands – sequence: 3 givenname: Anita surname: Stam fullname: Stam, Anita organization: Spaarne Gasthuis, Haarlem, Netherlands – sequence: 4 givenname: Dafni surname: Chondronasiou fullname: Chondronasiou, Dafni organization: Spaarne Gasthuis, Haarlem, Netherlands – sequence: 5 givenname: Sinead surname: Lougheed fullname: Lougheed, Sinead organization: Spaarne Gasthuis, Haarlem, Netherlands – sequence: 6 givenname: Petrousjka van den surname: Tol fullname: Tol, Petrousjka van den organization: Spaarne Gasthuis, Haarlem, Netherlands – sequence: 7 givenname: Karin surname: Jooss fullname: Jooss, Karin organization: Spaarne Gasthuis, Haarlem, Netherlands – sequence: 8 givenname: Ronald surname: Vuylsteke fullname: Vuylsteke, Ronald organization: Spaarne Gasthuis, Haarlem, Netherlands – sequence: 9 givenname: Alfons van den surname: Eertwegh fullname: Eertwegh, Alfons van den organization: Spaarne Gasthuis, Haarlem, Netherlands – sequence: 10 givenname: Tanja de surname: Gruijl fullname: Gruijl, Tanja de organization: Spaarne Gasthuis, Haarlem, Netherlands |
| BookMark | eNpFkc-O0zAQxiMEEkvZZ2AkzlnsOHYdbquKP5UqgUQ5W5N40rrY8eKkK-XGhZfjMXgSnBbEyeP5vplvpN-L4ukQByqKV5zdcS7Um5OburJiFSu_bPebpbhjgjVPipuKSV7yulLPi9txPDHGOBNCa31T_MqO3z9-7o8EKXqC2MN0DjGVNqEb3HAAP4eHIwzR0ghugCk7p_NFyd5xHicKroM9dOQ9uBCyNs3QzrDZ7-7LGlofu29oCdwIiR4JPdlFzm30YMm7R0rzJThRyN9wDtguUYTJz-U44YEgCzjEgG_B4oTQpxgA4fMRRyq3edKhf1k869GPdPv3XRVf37_bbz6Wu08ftpv7XdlyrZpSYSvsWmFTdVrLtWqU5qxjmnO-1lYS2rrFTlilpaprybSUra1Rt2vZ90KRWBXb614b8WQekguYZhPRmUsjpoPBNLnOk9HYI_VtZRnJmjeyWTectK2wZ7qzGcKqeH3d9ZDi9zONkznFcxry-aaSUjCmhVLZVV1dbfgfyJlZsJsFu1lom3_YzYJd_AG3E6dQ |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. 2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. |
| DBID | 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS DOA |
| DOI | 10.1136/jitc-2020-SITC2020.0309 |
| DatabaseName | ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China DOAJ Directory of Open Access Journals |
| DatabaseTitle | Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) |
| DatabaseTitleList | Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2051-1426 |
| EndPage | A336 |
| ExternalDocumentID | oai_doaj_org_article_8afaefb2d0e541959791e8d2af08cd10 jitc |
| GroupedDBID | 4.4 53G 5VS 7X7 88E 8FI 8FJ 9YT ABUWG ACGFS ADBBV ADRAZ ADUKV AFKRA AHBYD AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU DIK EBS EJD FYUFA GROUPED_DOAJ H13 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 M~E OK1 PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RMJ ROL RPM RSV SOJ UKHRP 3V. 7XB 8FK AZQEC DWQXO K9. PHGZM PJZUB PKEHL PPXIY PQEST PQUKI PRINS |
| ID | FETCH-LOGICAL-b1869-6ab3d76a92c8857696810c0811178d5ead4bac3d68564450855bd4a8b75ff36e3 |
| IEDL.DBID | DOA |
| IngestDate | Fri Oct 03 12:51:03 EDT 2025 Tue Oct 07 06:57:49 EDT 2025 Thu Apr 24 22:48:28 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | Suppl 3 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b1869-6ab3d76a92c8857696810c0811178d5ead4bac3d68564450855bd4a8b75ff36e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
| OpenAccessLink | https://doaj.org/article/8afaefb2d0e541959791e8d2af08cd10 |
| PQID | 2553008366 |
| PQPubID | 2040222 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_8afaefb2d0e541959791e8d2af08cd10 proquest_journals_2553008366 bmj_primary_10_1136_jitc_2020_SITC2020_0309 |
| PublicationCentury | 2000 |
| PublicationDate | 20201100 20201101 2020-11-01 |
| PublicationDateYYYYMMDD | 2020-11-01 |
| PublicationDate_xml | – month: 11 year: 2020 text: 20201100 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | Journal for immunotherapy of cancer |
| PublicationYear | 2020 |
| Publisher | BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| SSID | ssj0001033888 |
| Score | 2.1226966 |
| Snippet | BackgroundThe sentinel lymph node (SLN) is the first node to receive lymphatic drainage from the primary tumor and the site where naïve T cells are first... |
| SourceID | doaj proquest bmj |
| SourceType | Open Website Aggregation Database Publisher |
| StartPage | A336 |
| SubjectTerms | Biopsy Immunomodulators Immunotherapy Lymphatic system Lymphocytes Melanoma Monoclonal antibodies Targeted cancer therapy |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JbhQxELUgIJQLO2IgoDpwQya9ut1cUBgRESlEkRjQ3FpeQ4fp7mQWpLlx4ef4DL6EKo-HHJC4cGu1LdmSn12Ly-8x9qLAzaydK3jtcTcVJlFcCuk5sV0JeqwpgnTC5-Pq5EROp_VpTLgtYlnl9kwMB7UdDOXI9zPStyEqZfHm4pKTahTdrkYJjevsBslmE86raXWVY0kwAJMylnWludg_b5cGgYEh08ejyZg-XtEdAxoW3Z1H2v6_TuVgag7v_O8k77Lb0cmEgw0q7rFrrr_Pbn2I1-gP2E-czK_vPxAiQNWFMHhYrrphzm0UjIDZGlcZ-sG6BbQ9oJeIPUIL9t2wP7cGJkB5f2jDG5PlGvQaxpPjA16ARhv5VVkH7QKIJArNkKXmYDrBuhmVg6zDwJSgnLXdqlOahnLEuMzRZz1zgA2qHzr1GqiQFegpDCg4_YKWlx9BEBx5yD4dvpuM3_Mo6sA1qV9xoXRuK6HqzEiJwU5NhGgGHZM0raQtEdiFVia3QpboqpVURqdtoaSuSu9z4fJHbKcfeveYQWlqI6xNdOkxyMxyXYjMCY9OYZ7nPnUj9hJXtbnY0HY0IdzJRUMYaGjpmy0GGsLAiL2l1f_TnXi3w49hftbEbdxI5ZXzOrOJKwvi5anq1EmbKZ9IY9NkxPa2wGjiYbBorlDx5N_NT9luwGZ46rjHdpbzlXvGbppvy3Yxfx6w_Rs8WALI priority: 102 providerName: ProQuest |
| Title | 309 The role of tumor-draining lymph nodes in the tuning of systemic T cell immunity by CTLA-4 blockade is revealed by local delivery of tremelimumab in early-stage melanoma: data from a Phase-I trial |
| URI | https://jitc.bmj.com/content/8/Suppl_3/A336.full https://www.proquest.com/docview/2553008366 https://doaj.org/article/8afaefb2d0e541959791e8d2af08cd10 |
| Volume | 8 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral databaseCode: RBZ dateStart: 20130101 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://www.biomedcentral.com/search/ omitProxy: false ssIdentifier: ssj0001033888 providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals databaseCode: DOA dateStart: 20130101 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://www.doaj.org/ omitProxy: false ssIdentifier: ssj0001033888 providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources databaseCode: M~E dateStart: 20130101 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://road.issn.org omitProxy: false ssIdentifier: ssj0001033888 providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection databaseCode: 7X7 dateStart: 20130501 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://search.proquest.com/healthcomplete omitProxy: false ssIdentifier: ssj0001033888 providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central databaseCode: BENPR dateStart: 20130501 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://www.proquest.com/central omitProxy: false ssIdentifier: ssj0001033888 providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database databaseCode: PIMPY dateStart: 20130501 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: http://search.proquest.com/publiccontent omitProxy: false ssIdentifier: ssj0001033888 providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELagIMQF8Su2lNUcuKHQbH4ch1u7asVK7SqCBS0ny47tkrJJqt0s0t648HI8Bk_CjJOiShy4cEtiK7byjTMz9sw3jL1KcDFra5Mgd7iakjJUgeDCBcR2xSlZk_vSCZ_OsvlcLJd5caPUF8WE9fTA_Yc7FMop63RkQpsmxISS5RMrTKRcKErTJ1eFWX7DmfK7KyG6XkIMAV2TmB9eVl2JIoHO0ofZYkoXb-h0AVWKri8Hwv6__sdeyZw-ZA8G6xCO-lk9Yrds85jdOx_Ov5-wn_iuX99_ILZAYYHQOui2dbsOzFDpAVY7hAea1tgNVA2geYc9fAv27WmbqxIWQBv2UPnkkG4HegfTxdlRkIBG5fZVGQvVBojdCfWHoWav88DYFcVx7PzAtLO4quptrTQNZYkqOUBj88ICNqimrdVboAhUoBwWUFB8QZUZzMBXCnnKPp6eLKbvgqEaQ6CpbFXAlY5NxlUelUKgl5ITk1mJFsVkkgmTokQmWpWx4SJFGyul-DdtEiV0ljoXcxs_Y3tN29jnDNIyL7kxoU4deodRrBMeWe7Qmovj2E3siL1GUORVz7chvZ8Sc0kQSkJOXkMoCcIROybw_nQnwmz_AMVIDmIk_yVGI3ZwDb0cVvFGRlRTiei7-f7_GOMFu-8F0GcyHrC9br21L9nd8ltXbdZjdjtbZmN25_hkXrwfe3HGu2J2Xnz-DWpd-dc |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQcCFN2KhwBzghEzzdBwkhMpC1VW3q0osaG-pHdslZTcp-wDtjQt_hx_Cz-CXMOPN0gMStx64RbGVKM43L3tmPsaeJCjM2tqE5w6lKSkDxaWQjlO3K0HFmsJTJ3zoZ4OBHI3yww32Y10LQ2mVa53oFbVpStoj346I34ZaKYtXp585sUbR6eqaQmMFi327_Ioh2-xl7w3-36dRtPt22N3jLasA10S_xIXSscmEyqNSSvS2c-rIVaJlDMNMmhRXNtGqjI2QKfoKKeVxaZMoqbPUuVjYGJ97gV1EPZ5RsJeNsrM9nQADPinbNLIwFtsn1bxEIGKI9q437NLFczrTQEOmJyctTcBfVsCbtt3r_9ui3GDXWicadlaov8k2bH2LXT5o0wRus5_48b--fUcRAMqehMbBfDFppty0hBgwXiKKoW6MnUFVA3rBOMOP4NxVd-uqhCHQuQZUvoZmvgS9hO6wv8MT0OgDfFLGQjUDaoKFZtbQsHcNwNgxpbss_YtpA3ZcTRYTpelVljpKc_TJjy3ggKqbiXoBlKgLVOoDCg4_omfBe-AJVe6w9-eyknfZZt3U9h6DtMxLYUygU4dBdBTrRERWOHR64zh2oe2wZ4ii4nTVlqTw4VwsCsJcQVAr1pgrCHMd9prQ9mc69RX3N5rpcdGqqUIqp6zTkQlsmlDfoSwPrTSRcoEsTRh02NYaiEWr7GbFGQrv_3v4MbuyNzzoF_3eYP8Bu-rlwpd1brHN-XRhH7JL5Zd5NZs-8nIF7Oi8MfsbCZ5dTg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbhMxELZKiiou_CMCBeYAJ7Rkfx0vEkIlJSJqGkUioHLa2mu7bEl2S7IB5caFl-IReAyehBlnQw9I3HrgtlpbWcn5xvONPTMfY49jNGZlTOylFq0pzn3pCS6sR92uOBVrcied8H7YHY3E0VE63mI_NrUwlFa52RPdRq2rnM7IOyHp21ArZd6xTVrEeL__8uyzRwpSdNO6kdNYQ-TArL5i-LZ4MdjH__pJGPZfT3pvvEZhwFMkxeRxqSLd5TINcyGQeafUnStHLxkEXaETXOVYyTzSXCTIGxLK6VI6lkJ1E2sjbiL83UtsGyl5HLbY9nhwOP5wfsLjY_gnRJNUFkS8c1rUOcISA7a3g0mPHp7RDQe6NTU7bUQD_vIJztH1r_3PS3SdXW3oNeyt7eEG2zLlTbZz2CQQ3GI_cSF-ffuOxgGUVwmVhXo5q-aebqQyYLpCfENZabOAogTkxzjDjeDcdd_rIocJ0I0HFK66pl6BWkFvMtzzYlDIDj5JbaBYALXHQgesadiRBtBmSokwK_dhOpqdFrPlTCr6lKFe0x6y9RMDOCDLaiafA6XwAhUBgYTxR-Qc3gCc1Mpt9u5CVvIOa5VVae4ySPI051r7KrEYXoeRinlouEU6HEWRDUybPUVEZWfrhiWZC_QinhH-MoJdtsFfRvhrs1eEvD_TqeO4e1HNT7JmA8uEtNJYFWrfJDF1JOqmgRE6lNYXuQ78NtvdgDJrtsFFdo7Ie_8efsR2EKrZcDA6uM-uOBNx9Z67rFXPl-YBu5x_qYvF_GFjZMCOLxq0vwGuOGed |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=309%E2%80%85The+role+of+tumor-draining+lymph+nodes+in+the+tuning+of+systemic+T+cell+immunity+by+CTLA-4+blockade+is+revealed+by+local+delivery+of+tremelimumab+in+early-stage+melanoma%3A+data+from+a+Phase-I+trial&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Anita+Stam&rft.au=Dafni+Chondronasiou&rft.au=Karin+Jooss&rft.au=Jessica+Notohardjo&rft.date=2020-11-01&rft.pub=BMJ+Publishing+Group&rft.eissn=2051-1426&rft.volume=8&rft.issue=Suppl+3&rft_id=info:doi/10.1136%2Fjitc-2020-SITC2020.0309&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_8afaefb2d0e541959791e8d2af08cd10 |